Safety and efficacy of azithromycin in the treatment of community- acquired pneumonia in children

Pediatric Infectious Disease Journal

Volumn 17, Issue 10, 1998, Pages 865-871

  Harris, Jo Ann S ^a,e   Kolokathis, Antonia ^b   Campbell, Michael ^b   Cassell, Gail H ^c   Hammerschlag, Margaret R ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Azithromycin; Children; Community acquired pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; ERYTHROMYCIN ESTOLATE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BACTERIUM CULTURE; CHILD; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RASH; SERODIAGNOSIS; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNICABLE DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; FEMALE; HUMANS; INFANT; MALE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA;

EID: 0031763322     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199810000-00004     Document Type: Article

References (33)

1. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrobial Agents Chemother 1989;33:1413-8.
2. Frese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob Chemother 1990;25(Suppl A):39-47.
3. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob Chemother 1990;25(Suppl A):73-82.
4. Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J. Antimicrob Chemother 1996;37(Suppl C):37-44.
5. Nahata MC. Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis. Pediatr Infect Dis J 1995;14(Suppl):S39-44.
6. Nahata MC, Koranyi KI, Gadgil SD, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. J Antimicrob Chemother 1993;37:314-6.
7. Data on file. New York: Pfizer Inc., 1996.
8. Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J 1997;16:427-31.
9. Reed MD, Blumer JL. Azithromycin: a critical review of the first azalide antibiotic and its role in pediatric practice. Pediatr Infect Dis J 1997;16:1069-83.
10. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(Suppl 3A):5S-11S.
11. Scaglione F, DeMartini G, Dugnani S, Frashini F. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin and clarithromycin in infected cells. Chemotherapy 1993;39:416-23.
12. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (cp-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
13. Guay DRP. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-36.
14. McCracken GH Jr. Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J 1997;16:432-7.
15. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:790-8.
16. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activity of azithromycin, clarithromycin, lofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
17. Patel KB, Xuan D, Tessier PR, et al. Comparison of broncho-pulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
18. Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocytic infiltration into sites of localized infection. J Antimicrob Chemother 1996;37(Suppl C):9-19.
19. Hopkins SJ, Williams D. Clinical tolerability and safety of azithromycin in children. Pediatr Infect Dis J 1995;14(Suppl):S67-71.
20. Treadway G, Pontani D. Paediatric safety of azithromycin: world wide experience. J Antimicrob Chemother 1996;37(Suppl C):143-9.
21. Hamill G. Multi center evaluation of azithromycin and penicillin V in treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993;31(Suppl E):89-94).
22. Still JG. Management of pediatric patients with Group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14(Suppl):S57-61.
23. McLinn S. Double blind and open-label studies of azithromycin in management of acute otitis media in children: a review. Pediatr Infect Dis J 1995;14(Suppl):S62-6.
24. Roord JJ, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996;40:2765-8.
25. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. ed. 2. Villanova, PA: National Committee for Clinical Laboratory Standards, 1988.
26. Cassell GO, Blanchard A, Duffy L, Crabb B, Waites KB. Mycoplasmas. In: Howard BJ, Klass III J, Rubin SJ, Weissfield AS, Tilton RC, eds. Clinical and pathogenic microbiology. St. Louis: Mosby-Year Book, 1994;49:1-502.
27. Williamson J, Marmion BP, Kok T, Antic R, Harris RJ. Confirmation of fatal Mycoplasma pneumoniae infection by polymerase chain reaction detection of the adhesin gene in fixed lung tissue. J Infect Dis 1994;170:1052-53.
28. Van Kuppeveld FJM, van der Logt JTM, Angulo AF, et al. Genus and species-specific indentification of mycoplasmas by 16s or rRNA amplification. Applied Environmental Microbiology 1992;58:2606-2615.
29. Roblin PM, Dumornay W, Hammerschlag MR. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 1992;30:1968-71.
30. Block S, Hedrick J, Hammerschlag MR, Cassell GH. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J 1995;14:471-7.
31. Cassell GH, Gambil G, Duffy L. ELISA in respiratory infections of humans. In: Tully JG, Razin S, eds. Molecular and diagnostic procedures in mycoplasmology. vol II. San Diego, CA: Academic Press, 1996:123-36.
32. Cassell GH, Dmec J, Waites KB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother 1991;27(Suppl A):47-59.
33. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993;17:S37-46.